C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Grant of Options and Directors Dealing
29 September 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that a total of 5,950,000 options over ordinary shares of the Company were awarded pursuant to the 2014 Share Option Plan to certain employees, which includes 400,000 options each to Dr Clive Dix, Chief Executive Officer, Brad Hoy, Chief Financial Officer and Bhavna Hunjan, Chief Business Officer as set out below.
| Director | Position | Number of share options awarded | Option exercise price per share (pence) | Total number of options held |
| Dr Clive Dix | Chief Executive Officer | 400,000 | 15.1 | 1,245,000 |
| Brad Hoy | Chief Financial Officer | 400,000 | 15.1 | 1,400,000 |
| Bhavna Hunjan | Chief Business Officer | 400,000 | 15.1 | 1,255,556 |
The options have an exercise price of 15.1 pence, being the average 5-day VWAP of the ordinary shares prior to the 29 September 2023. The options can be exercised at any time between three and ten years of them being granted.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name(s)
| Dr Clive Dix | ||||
| 2 | Reason for the notification | |||||
|
|
| Chief Executive Officer, Director | ||||
| b) | Initial notification/Amendment
| Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | C4X Discovery Holdings plc | ||||
| b) | LEI | 213800UHNL82E323O870 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan
ISIN GB00BQQ2RV18 | ||||
| b) | Nature of the transaction
| Grant of options over ordinary shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information
| | ||||
| e) | Date of the transaction
| 29 September 2023 | ||||
| f) | Place of the transaction | London Stock Exchange - AIM | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name
| Brad Hoy | ||||
| 2 | Reason for the notification | |||||
|
|
| Chief Financial Officer, Director | ||||
| b) | Initial notification/Amendment
| Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | C4X Discovery Holdings plc | ||||
| b) | LEI | 213800UHNL82E323O870 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan
ISIN GB00BQQ2RV18 | ||||
| b) | Nature of the transaction
| Grant of options over ordinary shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information
| | ||||
| e) | Date of the transaction
| 29 September 2023 | ||||
| f) | Place of the transaction
| London Stock Exchange - AIM | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name
| Bhavna Hunjan | ||||
| 2 | Reason for the notification | |||||
|
|
| Chief Business Officer, Director | ||||
| b) | Initial notification/Amendment
| Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | C4X Discovery Holdings plc | ||||
| b) | LEI | 213800UHNL82E323O870 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan
ISIN GB00BQQ2RV18 | ||||
| b) | Nature of the transaction
| Grant of options over ordinary shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information
| | ||||
| e) | Date of the transaction
| 29 September 2023 | ||||
| f) | Place of the transaction | London Stock Exchange - AIM | ||||
- Ends -
Contacts
| C4X Discovery Holdings |
|
| Mo Noonan, Communications | +44 (0)787 6444977 |
| | |
| Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
| Freddy Crossley, Emma Earl (Corporate Finance) | +44 (0)20 7886 2500 |
| Rupert Dearden (Corporate Broking) | |
|
|
|
| C4X Discovery Media - Consilium Strategic Communications |
|
| Mary-Jane Elliott, Chris Gardner, Matthew Neal | +44 (0)203 709 5700 |
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.
We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
